The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
T cell repertoire analysis of non-small cell lung cancer patients treated with neoadjuvant nivolumab alone or in combination with ipilimumab (NEOSTAR trial).
 
Alexandre Reuben
No Relationships to Disclose
 
Jianjun Zhang
Honoraria - CancerNet; Geneplus; Innovent Biologics; Origimed; Roche; Sino-USA Biomedical Platform; Zhejiang Cancer Hospital
Consulting or Advisory Role - AstraZeneca; Capital Medical University; Geneplus
Research Funding - Merck
 
Heather Y. Lin
No Relationships to Disclose
 
Latasha Little
No Relationships to Disclose
 
Curtis Gumbs
No Relationships to Disclose
 
Hai T. Tran
No Relationships to Disclose
 
Linghua Wang
No Relationships to Disclose
 
Cara L. Haymaker
Research Funding - Idera; Nektar
 
Reza J. Mehran
No Relationships to Disclose
 
David C. Rice
No Relationships to Disclose
 
Garrett L. Walsh
No Relationships to Disclose
 
J. Jack Lee
Consulting or Advisory Role - Abbvie
 
Ignacio Ivan Wistuba
Consulting or Advisory Role - AstraZeneca/MedImmune; Asuragen; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Guardant Health; HTG Molecular Diagnostics; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche
Research Funding - 4D Molecular Therapeutics (Inst); Adaptimmune (Inst); Amgen (Inst); Bayer (Inst); EMD Serono (Inst); Genentech (Inst); Guardant Health (Inst); HTG Molecular Diagnostics (Inst); Karus Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); OncoPlex Diagnostics (Inst); Pfizer (Inst); Silicon Biosytems (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; HTG Molecular Diagnostics; MSD Oncology; Pfizer
 
Stephen Swisher
Travel, Accommodations, Expenses - Ethicon
 
Ara A. Vaporciyan
No Relationships to Disclose
 
Andrew Futreal
No Relationships to Disclose
 
Boris Sepesi
No Relationships to Disclose
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Merck; Novartis; Spectrum Pharmaceuticals
Research Funding - AstraZeneca (Inst); Spectrum Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations
 
Don Lynn Gibbons
Stock and Other Ownership Interests - Exact Sciences; Nektar
Consulting or Advisory Role - GlaxoSmithKline; Janssen Research & Development; Sanofi
Research Funding - AstraZeneca; Janssen Research & Development; Takeda
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; BerGenBio; Takeda
 
Tina Cascone
Honoraria - Bristol-Myers Squibb; Society for Immunotherapy of Cancer; Society for Immunotherapy of Cancer
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst)